152 results about "Blood proteins" patented technology

The present invention provides an array for rapidly identifying a host cell population capable of producing heterologous protein with improved yield and/or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment, or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

The present invention provides an array for rapidly identifying a host cell population capable of producing heterologous protein with improved yield and/or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment, or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

The invention relates to a biological adhesive for plywood and a preparation method thereof. The adhesive is a product obtained by chemically modifying animal blood protein grains with an amino compound and epoxy chloropropane, and the weight ratio of animal blood protein grains to amino compound to epoxy chloropropane is 10:1-5:1-5, wherein the animal blood protein grains are prepared from fresh animal blood, the grain size is greater than or equal to 50 meshes, and the solid content is 60-95 wt%; the amino compound is one or more than one of ammonia water, dimethylamine, diethylenetriamine, triethylenetetramine, polyvinylamine, polyethyleneimine and polyketoamine; and the fresh animal blood is blood of pigs, cows, sheep, chickens or ducks. The preparation method comprises the following steps of: chemically modifying the animal blood protein grains with the amino compound and epoxy chloropropane, and diluting the product to obtain the biological adhesive. The obtained adhesive reaches the bonding strength of No. I adhesives, the water resistance of an adhesive layer is increased, and the adhesive does not contain formaldehyde and has low cost and industrial popularization value.

The invention discloses pueraria root powder and a preparation method thereof. The pueraria root powder is characterized by comprising the following raw materials in percentage by weight: 40-60 percent of pueraria root powder, 10-30 percent of red Chinese date powder and 10-30 percent of carrot powder. The preparation method comprises the following steps: cleaning, peeling and slicing a pueraria root, superfine pulverizing and breaking wall of the pueraria root and drying the pueraria root by using hot air; carrying out cleaning, denucleating, slicing, color protection, vacuum freezing and drying and then superfine pulverizing on the red Chinese date; cleaning, slicing, preliminarily drying and then superfine pulverizing carrots and finally drying by hot air; and uniformly mixing the dried pueraria root powder, the red Chinese date powder and the carrot powder according to proper proportion and packaging to obtain the pueraria root powder. The invention has the functions of reducing pathogenic fire, neutralizing the effect of alcoholic drinks, enhancing the immunity, effectively reducing the serum cholesterol and enhancing the serum total protein and blood protein, traditional Chinese medicine values and health care efficacies of tonifying kidney and strengthening stomach, nourishing the blood and tranquilization and the like as well as the relieving function on nyctalopia.

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate. For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3′-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

A method and system for the extracorporeal treatment of blood to remove fluid from the fluid overloaded patient is disclosed that non-invasively measures osmotic pressure across a filter membrane of a blood filter. The filter is permeable to water and electrolytes, but not to blood protein. The osmotic pressure indicates the protein concentration in the blood. Osmotic pressure is used to detect when hypotension is about to occur in a patient, as a result of excessive blood volume reduction during treatment of the blood. Using the osmotic pressure measurement as a feedback signal, the rate of fluid extraction is automatically controlled to achieve the desired clinical outcome and avoid precipitating a hypotensive crisis in the patient.

A medical prosthetic device or medical implant containing a metal material (A) selected from the group consisting of titanium or an alloy thereof, zirconium or an alloy thereof, tantalum or an alloy thereof, hafnium or an alloy thereof, niobium or an alloy thereof and a chromium-vanadium alloy, wherein surface parts of the metal material (A) are coated with a layer of a corresponding hydride material (B) selected from titanium hydride, zirconium hydride, tantalum hydride, hafnium hydride, niobium hydride and chromium and/or vanadium hydride, respectively, said device or implant being characterised in that the layer of hydride material (B) comprises one or more biomolecule substances (C) associated therewith. The device or implant exhibits improved biocompatibility. The metal material (A) is preferably titanium. The biomolecule substance (C) may be selected from the following types of substances: Natural or recombinant bio-adhesives; natural or recombinant cell attachment factors; natural, recombinant or synthetic biopolymers; natural or recombinant blood proteins; natural or recombinant enzymes; natural or recombinant extracellular matrix proteins; natural or synthetic extracellular matrix biomolecules; natural or recombinant growth factors and hormones; natural, recombinant or synthetic peptide hormones; natural, recombinant or synthetic deoxyribonucleic acids; natural, recombinant or synthetic ribonucleic acids; natural or recombinant receptors; enzyme inhibitors; drugs; biologically active anions and cations; vitamins; adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (A TP); marker biomolecules; amino acids; fatty acids; nucleotides (RNA and DNA bases); and sugars.

The invention relates to a method using pancreatin-hydrolyzed swine blood corpuscle protein activated by swine fresh pancreas to produce swine blood protein peptide and haemoglobin, belonging to the field of feed additive. The invention takes fresh healthy swine blood corpuscle liquid as a raw material, pancreatin activated by swine fresh pancreas is hydrolyzed and filtered, the filtered supernatant is decolorized, then, the obtained protein liquid is dried to obtain the golden swine blood protein peptide, and the filter cake is dried to obtain the haemoglobin. The technical method has the following innovation points: 1, swine pancreas is taken as the raw material which is fresh and available, and the quality is controllable; 2, pancreatin activation method is simple, enzyme systems are rich, the activated enzyme has high activity, and the hydrolysis effect is good; 3, the swine fresh pancreatin has low cost, which is easy to carry out expanded production; 4, the swine blood corpuscle protein is hydrolyzed by pancreatin which can efficiently separate the haemoglobin thereof and can further prepare haemoglobin by drying the filter cake as the hydrolysate product, thus greatly improving the rate of multipurpose utilization of the swine blood corpuscle protein and avoiding resource waste.

It is intended to provide a blood purification membrane having excellent performance and showing little elution of blood and little adhesion of blood proteins or platelets. The above object can be achieved by using a moisten membrane, which is free from any membrane pore-sustaining agent and has a high water permeation dose and a large pore size, and lessening the pore size by drying the membrane after desolvation.

The invention relates to a method for preparing high-F value pig blood oligopeptide. The high-F value oligopeptide is prepared by adopting fresh pig blood as the raw material, carrying out enzymolysis on pig blood protein by utilizing protease and adsorbing and removing the aromatic amino acid by active carbon. The method comprises selection of the protease and an enzymolysis technical parameter thereof, selection of an adsorbing agent and an adsorbing technical parameter thereof, and the like and aims to improve an additional value of pig blood, reduce environmental pollution and provide a new path for preparing the high-F value oligopeptide by the deep processing on the pig blood. The high-F value pig blood oligopeptide prepared by using the method has the molecular weight concentrated in 800-1,200Da, good balance of composition of amino acid and free amino acid, aromatic amino acid content being smaller than 0.1 percent, F value being larger than 25 and the product yield being larger than 10.74 percent.

The present invention provides methods and compositions for producing heterologous protein with improved yield and/or quality. A library of randomized ribosomal binding site sequences is provided for the identification of a translation initiation region sequence optimal for expression of the heterologous protein. Also provided are novel ribosomal binding site sequences, and vectors and host cells having those sequences. The library of randomized sequences is useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

The invention provides a blood protein responsive type gamma-PGA (polyglutamic acid) hydrogel hemostasis material as well as a preparation method and an application thereof. The hemostasis material isprepared from a PHPA and DA (dopamine) molecule functionalized gamma-PGA polymer, a solvent with water as a main body, horseradish peroxidase and hydrogen peroxide, the synergetic enhancement effectof gamma-PGA, PHPA and DA on integration of wet high-strength wound is realized and the efficient blocking and hemostasis effect is achieved through Fe<3+> in gamma-PGA complexing blood, adsorption and blood coagulation of blood protein under the inducing action of benzene ring hydrophobic functional groups in PHPA and gel forming through oxidation and crosslinking by catechol groups in DA. The provided gamma-PGA hydrogel hemostasis material can effectively overcome the limitation of conventional pressing hemostasis method in application fields, besides, the problems that numerous hemostasis materials have poor blood responsiveness, poor integration capability for the wet bleeding wound and the like at present are solved, and the blood protein responsive type gamma-PGA hydrogel hemostasismaterial has the advantages of being high in hemostasis efficiency, good in biocompatibility, capable of allowing orthotopic injection of matched complicated wound types and the like and has broad market application prospects.

The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.

The invention provides a method for selectively modifying a heparin structure by using biological enzyme, which can improve anticoagulation activity of heparin, reduce combination of heparin with blood protein such as platelet factors and the like, and reduce toxic and side effects. The invention belongs to the field of biological medicine. The antithrombus and anticoagulation activities of the heparin derivatives prepared by the method are 2 to 3 times higher than common heparin medicament, the 2-O-sulfate and 6-O-sulfate contents are about 20 percent of the common heparin, and the combination capability of the heparin derivatives with the platelet factors is about 20 percent of the common heparin. The novel heparin derivatives have high anticoagulation activity and low side effect.

The invention discloses a cleaning effect monitoring card for cleaning and disinfecting equipment and a preparing method thereof. The cleaning effect monitoring card comprises a novel simulant pollutant and a stainless steel carrier. The novel simulant pollutant is prepared from protein, starch and fat. As protein, starch and a chromogenic substance are connected through chemical bonds, the problem of binding fastness between a chromogenic substance and a stimulant substance on a traditional indicator card is solved fundamentally. Pig blood protein is adopted as the protein component in the simulant pollutant, and human body blood components are highly simulated. The novel stimulant pollutant prepared in the formula is printed on the stainless steel carrier according to a specific pattern to prepare the cleaning effect monitoring card, and the two characteristics of blood are simulated further. Blood after operation is dried up on the surface of a metal instrument, the dried blood cannot be thoroughly cleaned away with water, and therefore the purposes of high simulation and accurate indication of the whole cleaning effect monitoring card are achieved. The cleaning effect monitoring card is easy and convenient to use, and results are easy to judge and read. The cleaning effect monitoring card is free of blood products, safe, nontoxic and suitable for all cleaning processes.